Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
12.89
-0.07 (-0.54%)
At close: Apr 28, 2026, 4:00 PM EDT
12.89
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:33 PM EDT
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Entrada Therapeutics stock have an average target of 21, with a low estimate of 20 and a high estimate of 23. The average target predicts an increase of 62.92% from the current stock price of 12.89.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $21 → $23 | Buy | Maintains | $21 → $23 | +78.43% | Apr 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +55.16% | Feb 18, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +55.16% | Feb 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +55.16% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +55.16% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
35.58M
from 25.42M
Increased by 39.97%
Revenue Next Year
53.66M
from 35.58M
Increased by 50.80%
EPS This Year
-3.99
from -3.47
EPS Next Year
-3.76
from -3.99
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 63.0M | 89.3M | ||||||
| Avg | 35.6M | 53.7M | ||||||
| Low | 14.7M | 24.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 147.8% | 150.8% | ||||||
| Avg | 40.0% | 50.8% | ||||||
| Low | -42.2% | -30.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.60 | -2.03 | ||||||
| Avg | -3.99 | -3.76 | ||||||
| Low | -4.56 | -4.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.